TD Asset Management Inc Decreases Holdings in DexCom, Inc. (NASDAQ:DXCM)

TD Asset Management Inc lessened its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 12.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 220,384 shares of the medical device company's stock after selling 30,537 shares during the period. TD Asset Management Inc owned about 0.06% of DexCom worth $15,050,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Jennison Associates LLC lifted its holdings in shares of DexCom by 37.7% during the 1st quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company's stock worth $718,632,000 after acquiring an additional 2,879,489 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in shares of DexCom by 171.0% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 3,194,829 shares of the medical device company's stock worth $218,175,000 after acquiring an additional 2,015,971 shares during the period. Woodline Partners LP bought a new stake in shares of DexCom during the 4th quarter worth approximately $63,338,000. Northern Trust Corp lifted its holdings in shares of DexCom by 22.2% during the 4th quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock worth $322,454,000 after acquiring an additional 753,857 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of DexCom during the 4th quarter worth approximately $41,295,000. Institutional investors own 97.75% of the company's stock.

Insider Activity at DexCom

In other DexCom news, EVP Sadie Stern sold 1,466 shares of the stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $88.99, for a total transaction of $130,459.34. Following the completion of the transaction, the executive vice president owned 106,689 shares in the company, valued at $9,494,254.11. This trade represents a 1.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $83.13, for a total transaction of $228,607.50. Following the transaction, the director owned 56,621 shares of the company's stock, valued at $4,706,903.73. This represents a 4.63% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,656 shares of company stock worth $2,412,191. 0.32% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts recently issued reports on DXCM shares. Morgan Stanley upped their price objective on shares of DexCom from $82.00 to $89.00 and gave the stock an "equal weight" rating in a research report on Tuesday, July 15th. Canaccord Genuity Group upped their price objective on shares of DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Robert W. Baird lowered their price objective on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. The Goldman Sachs Group initiated coverage on shares of DexCom in a research report on Friday, May 30th. They issued a "buy" rating and a $104.00 price target for the company. Finally, Barclays upped their price target on shares of DexCom from $93.00 to $98.00 and gave the company an "equal weight" rating in a research report on Wednesday. Four investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $99.89.

DexCom Stock Down 9.3%

Shares of DXCM stock traded down $8.29 on Thursday, hitting $80.77. The stock had a trading volume of 9,277,495 shares, compared to its average volume of 2,581,429. The business has a 50 day moving average of $84.75 and a 200 day moving average of $80.62. The stock has a market cap of $31.67 billion, a price-to-earnings ratio of 56.09, a price-to-earnings-growth ratio of 1.90 and a beta of 1.44. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 32.05%. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter last year, the company posted $0.43 earnings per share. The firm's quarterly revenue was up 15.2% compared to the same quarter last year. As a group, analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.